Novo Nordisk

Diversified pharma / diabetes & obesity

NVO · NYSE · Denmark

Share price · NVO

$39.43-6.28 (-13.74%) 3M

close as of 2026-11-18 · 24h delayed · vol 16.6M (1.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when NVO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 21 Sep 2026-8.0%
  2. 4 Aug 2026-6.0%
  3. 31 Jul 2026-8.8%
  4. 22 Jun 2026+6.2%
  5. 8 Jun 2026-4.5%
  6. 24 Apr 2026+6.9%
  7. 23 Feb 2026-16.4%
  8. 6 Feb 2026+9.9%
  9. 5 Feb 2026-8.2%
  10. 4 Feb 2026-6.2%

Share of unusual movement by asset

For each asset, the share of NVO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
cagrilintide/semaglutide (CagriSema)
events and moves
1626%
Semaglutide (Ozempic) (Ozempic)
events and moves
175%
Semaglutide (Wegovy) (Wegovy)
events and moves
344%
zenagamtide
events and moves
83%
Semaglutide (Wegovy tablets) (Wegovy)
events and moves
101%
insulin icodec (Awiqli)
events and moves
4shown from 8 days
cagrilintide
events and moves
3shown from 8 days
UBT251
events and moves
3shown from 8 days
IcoSema (Kyinsu)
events and moves
3shown from 8 days
Semaglutide (Rybelsus) (Rybelsus)
events and moves
3shown from 8 days
Etavopivat
events and moves
2shown from 8 days
CDR132L
events and moves
1shown from 8 days
Ziltivekimab
events and moves
1shown from 8 days
Coramitug
events and moves
1shown from 8 days
dasiglucagon (Zegalogue)
events and moves
1shown from 8 days
zaltenibart
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—6%
Other company news (earnings, financing, releases naming no asset)—36%
Sessions with no dated event—20%

Assets

(32 total)
32Total Assets
13Approved
8Phase 3 / Filed
11Phase 1–2 / Early
11Diseases
Quick filter:
Showing 32 of 32 assets
Target & Modality
dasiglucagon(Zegalogue)
Approved
Glucagon receptor (agonist)Peptide
Diabetes / Hypoglycemia
Severe Hypoglycemia
Approved
Insulin receptorPeptide
Type 2 DiabetesType 1 Diabetes
Approved
Insulin receptorPeptide
Type 2 DiabetesType 1 Diabetes
Approved
Insulin receptor (basal)Peptide
Type 2 DiabetesType 1 Diabetes
Approved
Insulin receptor (basal)Peptide
Type 2 DiabetesType 1 Diabetes
Approved
Insulin receptor (basal)Peptide
Type 2 Diabetes
Approved
GLP-1 receptorPeptide
Obesity
Approved
GLP-1 receptorPeptide
Type 2 DiabetesAtherosclerotic Cardiovascular Disease
Nedosiran(Rivfloza)
Approved
LDHA (lactate dehydrogenase A) mRNARNA / oligonucleotide
Chronic Kidney DiseasePrimary Hyperoxaluria
Primary Hyperoxaluria Type 1
Approved
GLP-1 receptorPeptide
Type 2 DiabetesChronic Kidney DiseaseAtherosclerotic Cardiovascular Disease
Approved
GLP-1 receptorPeptide
Type 2 DiabetesAtherosclerotic Cardiovascular Disease
Approved
GLP-1 receptorPeptide
Obesity
Approved
GLP-1 receptorPeptide
ObesityAtherosclerotic Cardiovascular DiseaseMASH / NASHHeart Failure
Heart Failure with Preserved Ejection Fraction
repaglinide(Prandin / NovoNorm)
US approval withdrawn
SUR1 (short-acting)Small molecule
Type 2 Diabetes
Phase 3
Amylin receptor · Amylin/calcitonin receptor (dual)Peptide
ObesityType 2 DiabetesChronic Kidney Disease

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(54 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
NNC0662-0419Phase 2Overweight, Obesity
Est. primary completion 2026-12-14 · NCT07184632 · CT.gov ↗
What to watch
2027 (19)
January 2027 (3)
UBT251Phase 2Overweight, Obesity
Est. primary completion 2027-01-14 · NCT07395687 · CT.gov ↗
What to watch
insulin icodec · AwiqliPhase 3Diabetes Mellitus, Type 1
Est. primary completion 2027-01-25 · NCT07076199 · CT.gov ↗
What to watch
ZiltivekimabPhase 3Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Est. primary completion 2027-01-29 · NCT06118281 · CT.gov ↗
What to watch
March 2027 (1)
Est. primary completion 2027-03-01 · NCT07011667 · CT.gov ↗
What to watch
May 2027 (4)
cagrilintidePhase 3Obesity, Overweight
Est. primary completion 2027-05-11 · NCT07220642 · CT.gov ↗
What to watch
cagrilintidePhase 3Overweight, Obesity, Type 2 Diabetes
Est. primary completion 2027-05-12 · NCT07220759 · CT.gov ↗
What to watch
CDR132LPhase 2Heart Failure
Est. primary completion 2027-05-16 · NCT06979375 · CT.gov ↗
What to watch
cagrilintidePhase 3Overweight, Obesity
Est. primary completion 2027-05-18 · NCT07745504 · CT.gov ↗
What to watch
June 2027 (3)
UBT251Phase 2Metabolic Dysfunction-associated Steatohepatitis (MASH)
Est. primary completion 2027-06-04 · NCT07145151 · CT.gov ↗
What to watch
cagrilintide/semaglutide · CagriSemaPhase 3Diabetes Mellitus, Type 2
Est. primary completion 2027-06-09 · NCT07817251 · CT.gov ↗
What to watch
Est. primary completion 2027-06-14 · NCT07639021 · CT.gov ↗
What to watch
August 2027 (2)
EtavopivatPhase 2Sickle Cell Disease
Est. primary completion 2027-08-20 · NCT05953584 · CT.gov ↗
What to watch
EtavopivatPhase 3Sickle Cell Disease
Est. primary completion 2027-08-27 · NCT06612268 · CT.gov ↗
What to watch
September 2027 (3)
NNC0662-0419Phase 2Diabetes Mellitus, Type 2
Est. primary completion 2027-09-03 · NCT07415954 · CT.gov ↗
What to watch
UBT251Phase 3Type 2 Diabetes
Est. primary completion 2027-09-24 · NCT07659574 · CT.gov ↗
What to watch
UBT251Phase 3Obesity & Overweight
Est. primary completion 2027-09-29 · NCT07648225 · CT.gov ↗
What to watch
October 2027 (1)
UBT251Phase 2Diabetes Mellitus, Type 2
Est. primary completion 2027-10-04 · NCT07668388 · CT.gov ↗
What to watch
November 2027 (2)
Semaglutide (Ozempic)Phase 3Diabetes Mellitus, Type 2
Est. primary completion 2027-11-07 · NCT03811561 · CT.gov ↗
What to watch
CDR132LPhase 2Heart Failure
Est. primary completion 2027-11-16 · NCT06979362 · CT.gov ↗
What to watch
2028 (22)
February 2028 (5)
Semaglutide (Wegovy tablets)Phase 3Overweight, Obesity
Est. primary completion 2028-02-22 · NCT07770841 · CT.gov ↗
What to watch
EtavopivatPhase 2Sickle Cell Disease
Est. primary completion 2028-02-23 · NCT06198712 · CT.gov ↗
What to watch
cagrilintide/semaglutide · CagriSemaPhase 3Obesity, Type 2 Diabetes
Est. primary completion 2028-02-23 · NCT07564414 · CT.gov ↗
What to watch
CoramitugPhase 2Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Est. primary completion 2028-02-29 · NCT06260709 · CT.gov ↗
What to watch
UBT251Phase 3Type 2 Diabetes
Est. primary completion 2028-02-29 · NCT07653477 · CT.gov ↗
What to watch
June 2028 (5)
cagrilintide/semaglutide · CagriSemaPhase 3Hypertension, Obesity
Est. primary completion 2028-06-01 · NCT07919405 · CT.gov ↗
What to watch
zenagamtidePhase 3Diabetes Mellitus, Type 2
Est. primary completion 2028-06-05 · NCT07931495 · CT.gov ↗
What to watch
zenagamtidePhase 3Obesity
Est. primary completion 2028-06-06 · NCT07503210 · CT.gov ↗
What to watch
zenagamtidePhase 3Obesity, Overweight, Obstructive Sleep Apnoea
Est. primary completion 2028-06-26 · NCT07571109 · CT.gov ↗
What to watch
zenagamtidePhase 3Overweight, Obesity
Est. primary completion 2028-06-27 · NCT07720271 · CT.gov ↗
What to watch
July 2028 (5)
zenagamtidePhase 3Type 2 Diabetes
Est. primary completion 2028-07-04 · NCT07931573 · CT.gov ↗
What to watch
zenagamtidePhase 3Obesity, Overweight, Obstructive Sleep Apnoea
Est. primary completion 2028-07-12 · NCT07571005 · CT.gov ↗
What to watch
zenagamtidePhase 3Diabetes Mellitus, Type 2
Est. primary completion 2028-07-24 · NCT07931599 · CT.gov ↗
What to watch
zenagamtidePhase 3Type 2 Diabetes, Chronic Kidney Disease
Est. primary completion 2028-07-31 · NCT07931547 · CT.gov ↗
What to watch
zenagamtidePhase 3Type 2 Diabetes, Cardiovascular Risk
Est. primary completion 2028-07-31 · NCT07797335 · CT.gov ↗
What to watch
August 2028 (3)
zenagamtidePhase 3Diabetes Mellitus, Overweight, Obesity
Est. primary completion 2028-08-07 · NCT07533175 · CT.gov ↗
What to watch
zenagamtidePhase 3Obesity, Knee Osteoarthritis (OA)
Est. primary completion 2028-08-14 · NCT07481630 · CT.gov ↗
What to watch
zenagamtidePhase 3Obesity, Overweight, Osteoarthritis, Knee
Est. primary completion 2028-08-14 · NCT07509307 · CT.gov ↗
What to watch
September 2028 (1)
UBT251Phase 3Obstructive Sleep Apnea, Obesity
Est. primary completion 2028-09 · NCT07767942 · CT.gov ↗
What to watch
October 2028 (1)
zenagamtidePhase 3Overweight, Obesity
Est. primary completion 2028-10-10 · NCT07668414 · CT.gov ↗
What to watch
November 2028 (1)
ZiltivekimabPhase 3Myocardial Infarction
Est. primary completion 2028-11-14 · NCT07301034 · CT.gov ↗
What to watch
December 2028 (1)
zenagamtidePhase 3Obesity, Overweight, Diabetes Mellitus, Type 2
Est. primary completion 2028-12-19 · NCT07400107 · CT.gov ↗
What to watch
2029 (8)
January 2029 (1)
zenagamtidePhase 3Obesity, Overweight
Est. primary completion 2029-01-11 · NCT07668401 · CT.gov ↗
What to watch
February 2029 (1)
zenagamtidePhase 3Overweight, Obesity
Est. primary completion 2029-02-05 · NCT07822061 · CT.gov ↗
What to watch
March 2029 (1)
UBT251Phase 3Obstructive Sleep Apnea, Obesity
Est. primary completion 2029-03 · NCT07806851 · CT.gov ↗
What to watch
April 2029 (1)
Semaglutide (Wegovy)Phase 3Non-alcoholic Steatohepatitis
Est. primary completion 2029-04-25 · NCT04822181 · CT.gov ↗
What to watch
June 2029 (2)
zenagamtidePhase 3Obesity
Est. primary completion 2029-06-26 · NCT07339423 · CT.gov ↗
What to watch
CoramitugPhase 3Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Est. primary completion 2029-06-29 · NCT07207811 · CT.gov ↗
What to watch
July 2029 (1)
zenagamtidePhase 3Obesity, Heart Failure
Est. primary completion 2029-07-23 · NCT07567001 · CT.gov ↗
What to watch
September 2029 (1)
cagrilintide/semaglutide · CagriSemaPhase 3Diabetes Mellitus, Type 2
Est. primary completion 2029-09-07 · NCT07282613 · CT.gov ↗
What to watch
2030 (4)
March 2030 (1)
cagrilintide + Semaglutide (Wegovy)Phase 3Overweight, Obesity
Est. primary completion 2030-03-20 · NCT07253285 · CT.gov ↗
What to watch
July 2030 (1)
UBT251Phase 2Obesity &Amp; Overweight, Chronic Kidney Disease
Est. primary completion 2030-07-11 · NCT07134335 · CT.gov ↗
What to watch
September 2030 (1)
zenagamtidePhase 3Cardiovascular Risk, Obesity
Est. primary completion 2030-09-16 · NCT07861100 · CT.gov ↗
What to watch
December 2030 (1)
EtavopivatPhase 3Sickle Cell Disease, Thalassemia
Est. primary completion 2030-12-30 · NCT06609226 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(42)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 November 2026Filing submittedEtavopivatNovo Nordisk submits the etavopivat NDA to the FDA
US, FDA · Novo Nordisk · Source ↗
13 November 2026Filing submittedEtavopivatNovo Nordisk submits the etavopivat MAA to the EMA
EU, EMA · Novo Nordisk · Source ↗
23 October 2026Approvalinsulin icodecFDA approves Awiqli for children 10 and older with type 2 diabetes
US, FDA · Source ↗
21 September 2026Topline resultcagrilintide/semaglutideREDEFINE 9: CagriSema 1.0/1.0 mg superior to placebo, primary endpoint met
Novo Nordisk · Source ↗
21 September 2026Topline resultcagrilintide/semaglutideREIMAGINE 5 (NCT06534411) Phase 3 met its primary endpoints
Novo Nordisk · Source ↗
7 September 2026Topline resultSemaglutide (Wegovy)STEP Young Phase 3 meets its primary endpoint
Novo Nordisk · Source ↗
4 August 2026Topline resultcagrilintide/semaglutideREIMAGINE 4: CagriSema non-inferior to tirzepatide on weight, not on HbA1c (mixed)
Novo Nordisk · Source ↗
31 July 2026Topline resultZiltivekimabPhase 3 ZEUS missed its MACE primary endpoint
July 2026ApprovalSemaglutide (Wegovy tablets)European Commission approves the Wegovy pill
EU, EMA/EC · Novo Nordisk · Source ↗
July 2026ApprovalSemaglutide (Wegovy)Wegovy 7.2 mg single-dose pen approved in the EU
EU, EMA · Source ↗
11 June 2026ApprovalSemaglutide (Wegovy)Wegovy pill (semaglutide tablets) approved in the UK
UK, MHRA · Source ↗
11 June 2026ApprovalSemaglutide (Wegovy tablets)Wegovy pill approved in the UK
UK, MHRA · Source ↗

The 12 most recent of 42 past events are shown.

Financial reports

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$46.8B$7.9B$4.2B—$18.0B operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$42.1B$7.0B$2.2B—$17.5B operating cash flowreport ↗
2023-FY$33.7B$4.7B$2.1B—$15.8B operating cash flowreport ↗
2022-FY$25.1B$3.4B$1.8B—$11.2B operating cash flowreport ↗
2021-FY$22.4B$2.8B$1.6B—$8.7B operating cash flowreport ↗

Insider transactions

This company files with the SEC but has no Section 16 insider reports. This is typical for foreign private issuers, which are exempt from Form 4 reporting.

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,262 reporting institutions held 325.8M shares ($11.3B, 7.4% of shares outstanding).

#InstitutionSharesValue
1Dodge & Cox19,333,750$710.5M
2LOOMIS SAYLES & CO L P17,017,315$625.4M
3FRANKLIN RESOURCES INC16,083,479$591.1M
4Capital International Investors11,795,850$424.8M
5SUSQUEHANNA INTERNATIONAL GROUP, LLP11,106,111$408.1M
6MORGAN STANLEY10,869,200$399.4M
7BANK OF AMERICA CORP /DE/10,769,699$395.8M
8FOLKETRYGDFONDET9,080,820$333.7M
9Fisher Asset Management, LLC9,021,103$331.5M
10ARROWSTREET CAPITAL, LIMITED PARTNERSHIP7,827,491$287.7M
11EVERETT HARRIS & CO /CA/6,424,661$236.1M
12TWO SIGMA INVESTMENTS, LP6,286,501$231.0M
13STATE FARM MUTUAL AUTOMOBILE INSURANCE CO6,142,778$225.7M
14STATE STREET CORP5,837,193$222.9M
15Capital World Investors5,209,427$191.3M